INK Edge

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Valeant Pharmaceuticals (T:VRX) has notable insider buying

Updated Tuesday Jun 13, 2017 01:14 AM EDT

Valeant Pharmaceuticals International, Inc. (VRX) has a high amount of executive buying compared to its large-cap peers over the past three months.

Osama Eldessouky, a Senior Officer, acquired 17,930 Common Shares on a direct ownership basis at a price of $12.510USD through an exercise of rights on June 7th, 2017. This represents a $302,631 investment into the company's shares and an account share holdings change of greater than 100%.

Valeant Pharmaceuticals is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

INK Edge Outlook

CONDITIONS:
Latest
6 months ago
1 year ago
Overall
Mostly Sunny
Mixed
Mixed
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at inkresearch.com.
Two-week free trial for first time users.
Go to Valeant Pharmaceuticals International, Inc. (VRX)'s company page

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Comment On!

INK Staff's picture
The INK Canadian Insider Index ends the day at 1,174.81-1.30 (-0.11%)
Jun 13, 2017 05:24 pm

Twitter

Search (past week) for $VRX.CA

  • No tweets found

Stocktwits